Tarlatamab and Next-Generation Targeted Agents Headline ESMO 2026 Lung Cancer Data
At ESMO 2026, Amgen's tarlatamab (Imdelltra) with AstraZeneca's durvalumab (Imfinzi) showed improved survival in lung cancer. Genentech's divarasib outperformed Amgen's sotorasib (Lumakras) and Bristol Myers Squibb's adagrasib (Krazati) in KRAS G12C-mutated NSCLC. AstraZeneca's osimertinib (Tagrisso) plus savolitinib (Orpathys) and Merck's sacituzumab tirumotecan (Kelun-Biotech) also showed promising results.
How this was made
The 30-second read
Why it matters
The most tradable signal is the combination and sequencing shift toward earlier maintenance or first-line use, supported by comparative OS/PFS hazard ratios and safety rates.
Market read
Traders may reprice oncology pipeline probabilities and competitive positioning based on phase 3 comparative efficacy and safety signals presented at ESMO.
What to watch
Safety and operational burden (CRS/neurotoxicity, edema, GI toxicity, outpatient monitoring) could slow uptake despite efficacy, and regulatory timelines for label expansion are not guaranteed.
Background
The article summarizes multiple phase 3 lung cancer studies presented at ESMO 2026, focusing on new efficacy endpoints and earlier-line positioning.
Ticker impact
Tarlatamab (Imdelltra) is reported in the phase 3 DeLLphi-305 trial, showing improved OS and PFS when moved into maintenance with durvalumab.
Likely upward bias as investors price in broader label potential and earlier-line adoption.
The article provides pivotal-style efficacy and safety rates from a phase 3 program, which can materially shift expectations for future approvals and uptake.
Durvalumab (Imfinzi) is paired with tarlatamab in DeLLphi-305 maintenance, with the combination reported to nearly double median OS in extensive-stage small cell lung cancer.
Likely supportive for AZN sentiment as the market considers durvalumab’s role in earlier-line maintenance strategies.
The article links durvalumab to a phase 3 regimen with strong OS/PFS hazard ratios, though it is not AZN-only data and regulatory timing is uncertain.
Sacituzumab tirumotecan (Kelun-Biotech, Merck) is reported in OptiTROP-Lung04 and OptiTROP-Lung06, showing improved OS and PFS versus chemotherapy or pembrolizumab-based regimens.
Likely upward bias as investors price in stronger clinical differentiation and potential label expansion.
The article includes final OS in one phase 3 study and PFS improvements in a first-line combination, both of which are material for ADC commercial prospects.
Adagrasib (Krazati) is included as a comparator in the phase 3 Krascendo 1 trial against divarasib and sotorasib in KRAS G12C-mutated NSCLC.
No clear directional call from this article alone.
The article’s new efficacy/safety details are centered on divarasib versus other agents, without presenting new adagrasib-specific outcomes as the primary disclosure.
Market effects
Reinforces momentum in lung cancer targeted therapies, including bispecific T-cell engagers, KRAS G12C inhibitors, MET-resistance strategies, and TROP2 ADCs.
Primarily impacts global oncology biotech sentiment rather than a specific region.
Phase 3 comparative efficacy data can shift international expectations for future approvals and competitive positioning across major oncology markets.
Counterpoint
Conference-reported phase 3 results may face follow-up scrutiny (maturity of OS, subgroup consistency, and real-world tolerability), so near-term re-rating could overshoot.
Key entities
- drugtarlatamab
Bispecific T-cell engager discussed in DeLLphi-305 maintenance, with improved OS and PFS versus durvalumab alone.
- drugdivarasib
KRAS G12C inhibitor discussed in Krascendo 1, showing improved PFS and OS versus sotorasib or adagrasib.
- drugsavolitinib
MET-targeted agent discussed in SAFFRON, improving PFS and OS with osimertinib versus platinum-pemetrexed.
- drugsacituzumab tirumotecan
TROP2-directed ADC discussed in OptiTROP-Lung04 and OptiTROP-Lung06, with improved OS and PFS signals.
